XML 65 R50.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Summary of Revenue Recognized under Various Agreements (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues | $ 685 | $ 1,188 | $ 1,550 | $ 627 | $ 2,277 | $ 2,209 | $ 3,048 | $ 3,498 | $ 4,050 | $ 11,032 | $ 11,251
Grant revenue |  |  |  |  |  |  |  |  | 683 | 2,688 | 5,138
Astra Zeneca |  |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Initial payment |  |  |  |  |  |  |  |  | 238 | 681 | 720
Subsequent payment |  |  |  |  |  |  |  |  | 892 | 2,554 |
Performance of research activities |  |  |  |  |  |  |  |  | 1,635 | 2,174 | 2,507
Total revenues |  |  |  |  |  |  |  |  | 2,765 | 5,409 | 3,227
Glaxo Smith Kline |  |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Initial payment |  |  |  |  |  |  |  |  |  | 2,524 | 1,702
Total revenues |  |  |  |  |  |  |  |  |  | 2,524 | 1,702
National Institute of Allergy and Infectious Diseases |  |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Grant revenue |  |  |  |  |  |  |  |  |  | 2,095 | 4,103
National Institutes of Health |  |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Grant revenue |  |  |  |  |  |  |  |  | $ 683 | $ 593 | $ 1,035

X
- Definition Subsequent payment. + References No definition available. + Details
Name: | dvax_SubsequentPayment
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_RevenueFromGrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |